

**ASX Announcement | 8 April 2021**  
**Visioneering Technologies (ASX:VTI)**

**Visioneering Completes Oversubscribed Security Purchase Plan**

**Atlanta, Georgia, USA, 7 April 2021 (8 April 2021, Sydney):** US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Visioneering Technologies, Inc (ASX: VTI) ('VTI' or 'The Company') is pleased to announce the completion of its security purchase plan (**SPP**).

Under the SPP, eligible holders were offered the opportunity to subscribe for up to A\$30,000 of CHES Depositary Interests (**New CDIs**) (representing new fully paid shares of Class A common stock) at an issue price of A\$0.017 per New CDI, together with one free new listed option (**New Option**) for every 2 New CDIs subscribed for. All New CDIs to be issued under the SPP will rank equally in all respect with the existing issued CDIs of Visioneering.

VTI sought to raise A\$1 million under the SPP. In accordance with its terms, and due to additional demand from eligible holders, VTI has increased the size of the SPP. The total amount raised under the SPP was A\$1,174,000.

VTI will issue the New CDIs (69,058,763) and New Options (34,529,326) under the SPP to eligible holders on Wednesday, 14 April 2021 in accordance with the timetable set out in the prospectus for the SPP dated 18 March 2021. Holding statements will be dispatched on Thursday, 15 April 2021.

"VTI is very pleased with the support we have received from our existing CDI holders under the SPP" said VTI's Chief Executive Officer, Dr Stephen Snowdy. "The funds received under the SPP add to the A\$22.1 million raised under the placement in late March, and will be used for international expansion, new product launches, conduct of clinical trials, to meet general working capital purposes and to fund VTI through to, or close to, break-even cash flow."

**Ends**

**This release was authorized by the CEO, Stephen Snowdy, PhD.**

**For more information, please contact:**

Stephen Snowdy  
CEO, Visioneering Technologies, Inc.  
Email: [ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

**About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is a health care company making innovative vision care products available to patients and eye care professionals. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from the healthcare industry to provide new solutions for adults and children in need of vision correction.

Headquartered in the United States, Visioneering designs, manufactures, sells and distributes contact lenses around the world. Its flagship product, NaturalVue® Multifocal contact lenses, are prescribed in the large addressable markets of nearsighted children and over-45 adults, and VTI is expanding its

portfolio of technologies to address a range of other vision care needs. Since its IPO in 2017, the company has grown operations across the US and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada, and Europe.

To learn more, please visit: [www.vtvision.com](http://www.vtvision.com)

### **Foreign ownership restrictions**

Visioneering's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Any forward-looking statements are provided as a guide only and should not be relied upon as an indication or guarantee of future performance. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. You should not place undue reliance on forward-looking statements because they speak only as of the date when made, and are subject to change without notice. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

Visioneering does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Visioneering may not actually achieve the plans, projections or expectations disclosed in forward-looking statements.

VTI-IR-ASX46